Miromatrix Medical Inc. (MIRO)

Market Cap	67.63M
Revenue (ttm)	31,115
Net Income (ttm)	-28.49M
Shares Out	20.90M
EPS (ttm)	-1.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,206
Open	3.47
Previous Close	3.49
Day's Range	3.20 - 3.65
52-Week Range	2.02 - 5.29
Beta	n/a
Analysts	Buy
Price Target	15.81 (+388.72%)
Earnings Date	n/a

About MIRO

Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. Its proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. The company has collaborations with The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 24, 2021
• Employees: 61
• Stock Exchange: NASDAQ
• Ticker Symbol: MIRO

Financial Performance

In 2021, MIRO's revenue was $33,066, a decrease of -28.94% compared to the previous year's $46,530. Losses were -$14.67 million, 42.3% more than in 2020.

Analyst Forecast

According to 8 analysts, the average rating for MIRO stock is "Buy." The 12-month stock price forecast is $15.81, which is an increase of 388.72% from the latest price.

Price Target

$15.81

(388.72% upside)

Analyst Consensus: Buy